Poor
Mostly Aligned
Patient Risk:
Low
Summary
Indication and mechanism-related claims are partially supported by the label, but all patient-assistance program eligibility/benefit claims are not verifiable from the provided FDA-approved prescribing information and substantially reduce overall alignment.
Category Scores
Accurate Statements
Vascepa is used to reduce the risk of heart attack, stroke, and other cardiovascular events in patients with high triglycerides and established cardiovascular disease.
Supported by 1 INDICATIONS AND USAGE (adjunct to maximally tolerated statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG levels and established cardiovascular disease).
Vascepa works by increasing the clearance of triglycerides from the bloodstream.
Supported by 12 CLINICAL PHARMACOLOGY (12.1 Mechanism of Action) (enhances TG clearance from circulating VLDL particles).
Unsupported Statements
Vascepa is a prescription medication (icosapent ethyl) used to treat high triglycerides.
Partially supported: label indication is more specific than 'high triglycerides' alone (requires adjunct context and specific patient populations/baseline therapy as described in 1 INDICATIONS AND USAGE).
Vascepa works by reducing the production of triglycerides in the liver.
Partially supported: label describes reduction of hepatic VLDL-triglyceride synthesis and/or secretion and multiple potential mechanisms; the claim over-specifies the mechanism.
To be eligible for the Vascepa Patient Aid Program, patients must be at least 18 years old.
Not verifiable from the provided FDA-approved prescribing information.
To be eligible for the Vascepa Patient Aid Program, patients must have a household income at or below 200% of the Federal Poverty Level (FPL).
Not verifiable from the provided FDA-approved prescribing information.
To be eligible for the Vascepa Patient Aid Program, patients must have commercial insurance, Medicare, or Medicaid.
Not verifiable from the provided FDA-approved prescribing information.
To be eligible for the Vascepa Patient Aid Program, patients must have a diagnosis of high triglycerides or established cardiovascular disease.
Not verifiable from the provided FDA-approved prescribing information.
To be eligible for the Vascepa Patient Aid Program, patients must have a valid prescription for Vascepa from a licensed healthcare provider.
Not verifiable from the provided FDA-approved prescribing information.
The Vascepa Patient Aid Program provides free Vascepa to eligible patients for up to 12 months.
Not verifiable from the provided FDA-approved prescribing information.
The Vascepa Patient Aid Program may provide discounts on Vascepa to eligible patients.
Not verifiable from the provided FDA-approved prescribing information.
The Vascepa Patient Aid Program may provide co-pay assistance to eligible patients to help reduce the co-pay amount for Vascepa.
Not verifiable from the provided FDA-approved prescribing information.
Contradictions
Important Omissions
No evaluation possible for boxed warnings, contraindications, detailed warnings/precautions, drug interactions, adverse reactions, monitoring, and storage/handling because the provided extracted claims do not address these label sections and those sections were not provided here.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-accurate mechanism/indication statements present; however, patient-assistance program eligibility/benefit details are not verifiable against the provided prescribing information. No contraindication/boxed-warning-related claims were made in the extracted response.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims pertain to a Patient Aid Program and are not supported or verifiable in the provided FDA-approved prescribing information.
Suggested Improvement
Remove or qualify Patient Aid Program eligibility/benefit claims unless supported by label text; align all drug-therapy and mechanism descriptions strictly to the wording and scope of 1 INDICATIONS AND USAGE and 12 CLINICAL PHARMACOLOGY (12.1).